AI-generated summary
The authors randomized 34 eyes of 32 patients with chronic central serous chorioretinopathy to a single session of low-fluence photodynamic therapy or three monthly ranibizumab injections. At 12 months, 88.9% of the photodynamic therapy group kept complete resolution of subretinal fluid without rescue treatment, versus 12.5% of the ranibizumab group. The authors describe this as overall superiority of low-fluence photodynamic therapy, though the trial was small and single-center.
- Participants
- 32
- Who or what was studied
- Patients with chronic central serous chorioretinopathy (34 eyes of 32 patients), with more than 6 months of symptoms or recurrent disease
- Limits stated in the abstract
- Small, single-center trial with 34 eyes split between two arms of 18 and 16, and rescue treatment was permitted, which may affect the comparison.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photodynamic therapy, Fluence, Primary outcome. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.